Results 211 to 220 of about 8,916 (246)
Some of the next articles are maybe not open access.
American Journal of Transplantation, 2017
Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes. Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed ...
Eskandari, S. K. +3 more
openaire +1 more source
Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes. Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed ...
Eskandari, S. K. +3 more
openaire +1 more source
Immunoproteasome responds to injury in the retina and brain [PDF]
Journal of Neurochemistry, 2008 AbstractIt is well known that immunoproteasome generates peptides for MHC Class I occupancy and recognition by cytotoxic T lymphocytes (CTL). The present study focused on evidence for alternative roles for immunoproteasome. Retina and brain were analyzed for expression of immunoproteasome subunits using immunohistochemistry and western blotting under ...
Deborah A Ferrington +2 more
exaly +3 more sources
A patent review of immunoproteasome inhibitors
Expert Opinion on Therapeutic Patents, 2018The ubiquitin-proteasome system is responsible for maintaining protein homeostasis and regulating a variety of cellular processes. The constitutive proteasome is expressed in all cells while the immunoproteasome (IP) is predominantly found in cells of hematopoietic origin.
Eva, Ogorevc +3 more
openaire +2 more sources
The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry, 2011The proteasome, a large multisubunit protease complex, has been extensively investigated over the years, greatly enhancing our understanding of critical roles that the proteasome plays in cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has validated the proteasome as an anticancer target.
Wooin, Lee, Kyung Bo, Kim
openaire +2 more sources
Development of isoquinolinone derivatives as immunoproteasome inhibitors
Bioorganic & Medicinal Chemistry Letters, 2022The inhibition of immunoproteasome is considered nowadays a promising strategy for the treatment of hematologic malignancies. In this paper we report the design, synthesis, and biological evaluation as immunoproteasome inhibitors of a new series of isoquinolinone derivatives characterized by a (E)-prop-1-ene fragment that connects the heterocycle to a ...
Ettari R. +5 more
openaire +3 more sources
Immunoproteasome as a Target for Prodrugs
Journal of Medicinal ChemistryImmunoproteasome (iCP) is a proteasome isoform that is expressed under inflammatory conditions such as cytokine interferon-γ exposure. The iCP has different catalytic subunits other than the standard CP (standard core particle), allowing the production of major histocompatibility complex class I (MHC-I) compatible peptides for eventual T-cell ...
Christine S. Muli +2 more
openaire +2 more sources
Emerging role of immunoproteasomes in pathophysiology
Immunology & Cell Biology, 2016The immunoproteasome is a proteasome variant that is found only in jawed vertebrates. It is responsible for degrading intracellular proteins to generate a major source of peptides with substantial major histocompatibility complex I binding affinity. The immunoproteasome also has roles in T‐cell survival, differentiation and proliferation in various ...
Gagandeep, Kaur, Sanjay, Batra
openaire +2 more sources
Immunoproteasome-Specific Inhibitors and Their Application
2012Immunoproteasomes (IPs) containing the interferon-inducible subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7) alter proteasomal cleavage preference, optimise the generation of peptide ligands of MHC class I molecules, alter cytokine profile, influence T-helper cell differentiation, and play a role in T-cell survival.
Michael, Basler, Marcus, Groettrup
openaire +2 more sources
Immunoproteasomal Processing of Isolevuglandin Adducts in Hypertension
2023SUMMARY Abstract Figure Graphical Abstract Isolevuglandins (isoLGs) are lipid aldehydes that form in the presence of reactive oxygen species (ROS) and drive immune activation.
Néstor de la Visitación +10 more
openaire +2 more sources
Immunoproteasom: drug development for xenotransplantation
Xenotransplantation, 2012The majority of cellular proteins are degraded by proteasomes within the ubiquitin‐proteasome ATP‐dependent degradation pathway. Products of proteasomal activity are short peptides which are further hydrolysed by proteases to single amino acid. Some peptides though can escape the degradation, being selected and uptaken by MHC class I molecules for ...
openaire +1 more source